FindTrial
Sign In

Amiodarone therapy for treatment of fontotemporat dementia caused by progranulin deficiency

- Rescue of Progranulin HaploInsufficiency in Frontotemporal Dementia - ReProIn-FTD

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-004571-37-IT
Enrollment
Unknown
Registered
2012-02-17
Start date
2012-02-21
Completion date
Unknown
Last updated
2012-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

frontotemporal dementia associated to progranulin deficit MedDRA version: 14.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders

Interventions

Pharmaceutical Form: Tablet INN or Proposed INN: AMIODARONE CAS Number: 1951-25-3 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Conc

Sponsors

AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: age > 18 years old Mild-moderate Frontotemporal Dementia associated to Progranulin deficit (Clinical Dementia Rating= 0.5-1) Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 4 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 1

Exclusion criteria

Exclusion criteria: a) Any medical contidion which may intefere with the possibility to partecipate to this study b) Severe Frontotemporal Dementia (Clinical Dementia Rating >1)

Design outcomes

Primary

MeasureTime frame
Primary end point(s): to modify le progression of frontotemporal dementia associated with progranulin deficit;Main Objective: - To rescue Progranulin deficit - to evaluate the progression of Frontotemporal Dementia caused by progranulin deficit;Secondary Objective: na;Timepoint(s) of evaluation of this end point: 18 months—

Secondary

MeasureTime frame
Secondary end point(s): to rescue progranulin deficit;Timepoint(s) of evaluation of this end point: 18 months—

Countries

Italy

Contacts

Public ContactCoordinamento Ricerca Clinica

A.O. Spedali Civili di Brescia

carmen.terrarolo@spedalicivili.brescia.it0303996851

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026